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a  b  s  t  r  a  c  t
During  therapeutic  interventions,  blood  concentrations  of  intravenously  applied  drugs  are
higher, and  their  onset  of  pharmacological  action is faster  than  with  other  routes  of  drug
administration.  However,  acute  drug  therapy  often  produces  nephrotoxic  side  effects,  as
commonly  seen  after treatment  with  Ketorolac  or  Gentamicin  leading  to  questions  about
their use,  especially  for patients  at risk  for acute  renal  failure.  Omega-6(n-6)  and  omega-
3(n-3)  polyunsaturated  fatty  acids  (PUFA)  affect  eicosanoid  metabolism,  which  plays  a
role in  the  regulation  of inﬂammation.  Eicosanoids  derived  from  n-6 FA  have  proinﬂam-
matory  and  immunoactive  functions,  whereas  eicosanoids  derived  from  n-3  PUFA  have
anti-inﬂammatory  and  cytoprotective  properties.  We  hypothesized  that  providing  such
injectable  drugs  with  nephrotoxic  potential  in  combination  with  n3-PUFAs  from  the outset,
might afford  rapid cytoprotection  of  renal  cells,  given  the  recent  evidence  that  intra-
venously  administered  n3-PUFAs  are  rapidly  incorporated  into  cell  membranes.  We  used
intraglomerular  mesangial  cells  (MES13)  that  are  sensitive  to treatment  with  Ketorolac  or
Gentamicin instead  of  proximal  tubular  cells  which  do not  respond  to Ketorolac.  We  found
a signiﬁcant  inhibition  of  Ketorolac  (0.25,  0.5, 1 mM)  or Gentamicin  (2.5,  5 mM)  induced
cytotoxicity  after  pretreatment  of  MES13  cells  with  0.01%  of  20%w/v  LipOmega-3  Emul-
sion 9/1,  containing  90:10  wt/wt  mixture  of  ﬁsh  oil derived  triglycerides  to medium  chain
triglycerides.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
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1. Introduction
The underlying toxicity of many drugs to vital organs
of  the body is often a result of localized ischemia which
triggers a series of complex biochemical events related
to  hypoxia, inﬂammation, and with the potential for sub-
sequent  oxidative stress with reperfusion, all of which
is is an open access article under the CC BY-NC-ND license
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induce cellular damage. This is particularly true in the
critically ill patient in the intensive care unit with an inef-
fective  circulating blood volume (e.g., mean arterial blood
pressure < 60 mmHg) causing moderate to severe hypoper-
fusion  to vital organs such as the kidney, producing acute
tubular necrosis. In this setting, the likelihood or severity of
acute  kidney injury (AKI) can be aggravated by the concur-
rent  administration of injectable nephrotoxic drugs, with
mortality  rates from acute renal failure ranging from 25 to
64%  [21].
Thus, the combined impact of ischemic insult to aerobic
tissues, from both disease(s) and drug(s), greatly accentu-
ates  the potential for damage to vital organs in the critically
ill.  During ischemia, oxygen, as well as other vital nutrients
become limiting to dependent tissues such as the kidneys,
causing mitochondrial dysfunction [4]. Blood ﬂow to the
kidneys  as a fraction of the total cardiac output is approx-
imately 20% [11]. Thus, even limited reductions in normal
blood  ﬂow to the kidneys resulting from a compromised
circulating blood volume as described above, can have dev-
astating  consequences for renal tissues, especially during
the  concomitant intravenous administration of nephro-
toxic  drugs in full therapeutic doses.
Polyunsaturated omega-3 or n-3 fatty acids (n3-PUFAs),
such as eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) from ﬁsh oil triglycerides, have been shown to
mitigate  the nephrotoxic effects of cyclosporine A in an
experimental animal model [9]. Animals were pre-fed via
gastric  lavage for 14 days prior to nephrotoxic drug expo-
sure  in order to obtain sufﬁcient incorporation of n3-PUFAs
into  plasma cell membranes to exert their cytoprotec-
tive effects. Although this approach would seem viable
in  patients receiving such therapy in the long-term set-
ting  (e.g., lifelong immunosuppression with cyclosporine
A for organ transplantation), the requisite time course for
pre-treatment with n3-PUFAs in the acute care setting in
patients  with, for example, life-threatening blood infec-
tions,  or, for acute postoperative pain, is not achievable.
That is, acute drug therapy is often vital with a potential
nephrotoxin given intravenously to achieve higher con-
centrations more rapidly and completely than achievable
with oral administration in order to improve therapeu-
tic efﬁcacy, which also increases the potential for adverse
renal  effects that are generally related to drug levels.
However, we hypothesize that providing such injectable
drugs in combination with n3-PUFAs from the outset,
may  afford rapid cytoprotection of renal cells, especially
in  light of recent evidence that intravenously adminis-
tered n3-PUFAs are rapidly incorporated into plasma cell
membranes within 1 h of infusion after a single dose [6].
Once  incorporated into cell membranes, a key step to exert
cytoprotection, n3-FAs dramatically modulate the body’s
response to inﬂammation, oxidative stress, ischemia and
immune  function through several downstream bioactive
mediators, (e.g., cytokines, prostaglandins, thromboxanes,
leukotrienes, resolvins, protectins, etc.) [2].
The purpose of this investigation was to study the
potential cytoprotective effects of omega-3 fatty acids
against known nephrotoxic drugs in an in vitro murine
intraglomerular mesangial cell model to establish proof of
concept.  The combination of “cytoprotective excipients”eports 1 (2014) 843–857
with selected nephrotoxic drugs constitutes a unique
opportunity for potentially safer intravenous therapy in the
acute  care setting, where the inclusion of omega-3 fatty
acids  could also serve as a secondary supportive, but impor-
tant,  active pharmaceutical ingredient, to form a novel
therapeutic drug vehicle.
2.  Material and methods
At  the outset, SV 40-transformed mouse mesangial cells,
MES  13 (CRL-1927TM; purchased from the American Type
Culture Collection [ATCC-LGC Standards GmbH], Wesel,
Germany) were used.
The  selection of these cells, as opposed to proximal
tubule cells typically associated with renal tubular dam-
age,  was  based on observations that nephrotoxicity from
drugs  such as Gentamicin is related to their direct effect
(proliferation and apoptosis) on cultured mesangial cells
[20]  In contrast to MES13, the HK-2, an immortalized prox-
imal  tubule epithelial cell line from normal adult human
kidney have not shown any response after treatment with
Ketorolac (not shown). Thus, we  chose to study MES13 and
two  nephrotoxins typically given by intravenous adminis-
tration in the ICU setting: The potent analgesic, Ketorolac,
and the aminoglycoside antibiotic, Gentamicin.
2.1. Cell lines and culture conditions
The MES  13 cells were cultured in ATCC complete
growth medium: the basic medium for these cell lines
is  a 3:1 mixture of ATCC-formulated Dulbecco’s Modiﬁed
Eagle’s Medium [ATCC (DMEM)], and Ham’s F12 medium
(PAA  Laboratories GmbH, Cölbe, Germany) with 14 mM
HEPES,  supplemented with 5% fetal bovine serum (FBS),
100  U/ml penicillin, 0.1 mg/ml  streptomycin. Under these
culture  conditions the MES  13 retained many of the dif-
ferentiated characteristics of mesangial cells. Cells were
maintained at 37 ◦C in a humidiﬁed atmosphere of 5% CO2
and 95% air; the medium was changed every 48 h.
2.2.  Substances under test
2.2.1. The control emulsions
20%w/v Lipofundin N, containing 20% soybean oil only
triglycerides, Lot No 111258082.
2.2.2.  The test emulsions
20%w/v LipOmega-3 Emulsion 5/5, containing
50:50wt/wt mixtures of ﬁsh oil (FO) derived triglyceri-
des and (MCTs), solution number 356. Lot No 11182049,
20%w/v LipOmega-3 Emulsion 7/3, containing 70:30wt/wt
mixtures of ﬁsh oil (FO) derived triglycerides and medium
chain  triglycerides (MCTs), respectively, solution number
358.  Lot No 11182050; 20%w/v LipOmega-3 Emulsion 9/1,
containing 90:10wt/wt mixtures of ﬁsh oil (FO) derived
triglycerides and medium chain triglycerides (MCTs),
respectively, solution number 359. Lot No 11202049. All
lipid  emulsions by B. Braun Melsungen AG, Melsungen,
Germany.
The ﬁsh oil used in all 3 ﬁsh oil-containing emulsions
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he manufacturer citing the following minimum omega-
 concentrations: Total—60%; EPA—33%; DHA—22%, but
e  have measured (GC/MS) the total at nearly 70% and
PA  + DHA of 62% (1.5:1 ratio). So given this information,
e estimate the average EPA + DHA in the oil to be 60%
nriched. From this, the test emulsions should contain the
pproximate amounts of FO, EPA and DHA (in g/dl) as fol-
ows:  9/1 (18 FO, 10.8 EPA + DHA, 6.5 EPA, 4.3 DHA), 7/3
14  FO, 8.4 EPA + DHA, 5.1 EPA, 3.3 DHA), 5/5 (10 FO, 6
EPA  + DHA, 3.6 EPA, 2.4 DHA).
.2.3.  The nephrotoxic drugs
Ketorolac  Tromethamine Injection, USP, I.V./I.M.
0 mg/ml  (Hospira, Inc., Lake Forest USA.); Gentami-
in solution, 50 mg/ml, (Sigma-Aldrich, Taufkirchen,
ermany).
.3. Determination of cytotoxic concentrations of
etorolac and Gentamicin
4  × 103 (for Gentamicin test) or 8 × 103 (for Ketorolac
est) MES  13 100 l medium/well was seeded in 96-well
lates (BD FalconTM, Becton Dickinson GmbH, Heidel-
erg, Germany). After 48 h, the medium was changed and
ifferent  concentrations of Ketorolac (0.1–1 mM)  and Gen-
amicin  (0.5–5 mM)  were tested after 24 h treatment, and
ytotoxicity was measured as described below (see Section
.5).  As a control (=0% cytotoxicity), we used cells cultured
ith  medium alone, i.e., without Ketorolac or Gentamicin
reatment.
.4. Determination of the protective effects of the
mulsions against cytotoxicity from Ketorolac or
entamicin
4  × 103 or 8 × 103 MES  13 was seeded in 100 l
edium/well in 96-well plates (BD FalconTM, Becton
ickinson GmbH, Heidelberg, Germany). After 48 h, the
edium  was changed and 50 l/well medium was added.
mmediately the emulsions were dispersed in medium at
0  l/well at concentrations of 0.01%, 0.02% or 0.04% (end
oncentration: 0.005%, 0.01% or 0.02%) added to the cells.
s  a negative control, we used cells which received 100 l
edium  without any emulsions. After 24 h pre-treatment
r pre-incubation with the above mentioned emulsions,
he following concentrations of Ketorolac were added to
he  cells for the next 24 h together with the emulsions:
.1 mM,  0.25 mM,  0.5 mM or 1 mM,  whereas Gentamicin
as added at 0.5 mM,  1 mM,  2.5 mM or 5 mM.  The dif-
erent concentrations of Ketorolac or Gentamicin were
dded  to the cells either pre-treated (24 h) with emulsions
potential protective effect) or without emulsion (cyto-
oxicity of Ketorolac or Gentamicin [control]). Additional
ontrols were performed: cells pre-incubated with emul-
ions,  however, without Ketorolac or Gentamicin (control
f  the emulsion effect) as well as cells without emulsion
re-treatment, and without Ketorolac or Gentamicin (con-
rol  = 0% cytotoxicity).
Finally, co-incubation or co-treatment with the test
mulsions plus Ketorolac or Gentamicin was performed.
rieﬂy, different concentrations of Ketorolac (0.5 mM oreports 1 (2014) 843–857 845
1  mM)  and Gentamicin (2.5 or 5 mM),  were added to the
cells  at the same time as the emulsions (0.005%, 0.01%
or  0.02%) and incubated for 24 h or 48 h. Cytotoxicity was
measured as described below (see Section 2.5).
2.5. Determination of cell death or cytotoxicity
Cell cytotoxicity was assessed using PrestoBlueTM [3]
reagent (Invitrogen-Life Technologies GmbH, Darmstadt,
Germany). PrestoBlueTM reagent is a resazurin-based solu-
tion  that functions as a cell viability indicator by using
the  reducing power of living cells to quantitatively mea-
sure  the viability. When added to cells, the PrestoBlueTM
reagent – containing a non-ﬂuorescent, cell-permeant
compound – is modiﬁed by the reducing environment
of the viable cells, becoming highly ﬂuorescent, which
can  be detected using ﬂuorescence or absorbance mea-
surements. PrestoBlueTM reagent is more sensitive than
AlamarBlue®, which is a redox indicator of enzyme activ-
ity  widely used in whole organism screening [18] and is
extensively used in screening tests of viability and cytotox-
icity  [18,22,12,29,1,27]. PrestoBlueTM was directly added to
the  cells in the culture medium at a ﬁnal concentration of
10%.  Thereafter the plates were returned to the incubator.
30  min, 1 h, 2 h, 3 h and 4 h after addition of PrestoBlueTM
the optical density (OD) was measured at 570 nm and
600  nm (as reference) with a SUNRISE ELISA-reader (Tecan,
Salzburg, Austria). Results are expressed in % of cytotoxic-
ity  [100 − (OD570/600 of samples × 100/OD570/600 of control
without substances)].
2.6.  RNA-preparation and reverse transcription
polymerase chain reaction (RT-PCR)
RNA was  extracted from 1 × 106 cells using peq-
GOLD Isolation Systems TriFastTM (PEQLAB Biotechnologie
GmbH Erlangen Germany) according to the manufac-
turer’s speciﬁcations. RNA concentration and purity were
determined by A260 and A280 (A260/A280 = 1.7 to 2.0)
measurements using a NanoDrop 2000c Spectrophotome-
ter (Thermo Scientiﬁc, Schwerte, Germany). Total RNA
integrity was  conﬁrmed by lab-on-a-chip technology, using
an  RNA 6000 NanoChip kit on an Agilent 2100 Bioan-
alyzer (Agilent Technologies, Waldbronn, Germany). An
aliquot  of 1 g total RNA was treated with 1 unit of RNAse
(Thermo Scientiﬁc, St. Leon-Rot, Germany) for 30 min
at  37 ◦C. Reverse transcription of RNA (1 g) was  per-
formed with 500 ng oligo (dT)12–18 primer, 20 unit of
the  Afﬁnity Script multiple temperature cDNA synthe-
sis  (Agilent) and 24 unit of Ribo LockTM RNAse inhibitor
(Fermentas) for 1 h at 42 ◦C. The cDNA was used for
quantitative real-time polymerase chain reaction (qRT-
PCR)  using the QuantiTect/primerAssays from QIAGEN
GmbH (Hilden, Germany). The mRNA expression was
analyzed for: BCL2-associated X protein, NM 007527
(BAX), amplicon length 78 bp; B-cell CLL/lymphoma 2,
NM  009741 (BCL2), amplicon length 104 bp; caspase 3,
apoptosis-related cysteine peptidase, NM 009810 (Casp3),
amplicon length 150 bp; prostaglandin-endoperoxide syn-
thase  2, NM 011198 (PTGS2, cyclooxygenase-2, COX-2),
amplicon length 95 bp; glutathione reductase, NM 010344
cology R
out statistical analyses. After testing for Normality
(by Shapiro–Wilk), the unpaired Student’s t-test or846 G.A. Bonaterra et al. / Toxi
(GSR), amplicon length 92 bp; glutathione synthetase,
NM 008180 (GSS), amplicon length 95 bp; proliferating
cell nuclear antigen NM 011045 (PCNA), amplicon length
104  bp, thromboxane A synthase 1; NM 011539 (TBXAS),
amplicon length 179 bp. The following reference gene was
used:  Ribosomal protein L32, NM 172086 (RPLP32), ampli-
con  length 88 bp. cDNAs were ampliﬁed with Brilliant III
Ultra-Fast  SYBR Green QRT-PCR Master Mix  (Stratagene-
Agilent Technologies, Waldbronn, Germany). The thermal
proﬁle  consisted of 1 cycle at 95 ◦C for 3 min  followed,
40 cycles at 95 ◦C (10 s) and 60 ◦C (20 s). Ampliﬁcation
and data analysis were performed using the Mx3005PTM
QPCR System (Stratagene). The data were analyzed using
the  relative standard curve method. For each unknown
sample, the relative amount was calculated using lin-
ear  regression analysis from their respective standard
curves. For relative quantiﬁcation, a standard curve was
generated from a pool of cDNA. Speciﬁcity of the ampli-
ﬁed  product was conﬁrmed by melting curve analysis
(55–95 ◦C), and additionally, by using 2% agarose gel
electrophoresis to verify the amplicon size in conjunc-
tion with melting curve data. The NormFinder software
program was used to ascertain the most suitable ref-
erence gene to normalize the RNA input as described
earlier [26].
2.7. Biochemical determination of total glutathione
(tGSH), glutathione disulﬁde (GSSG), and reduced
glutathione (rGSH)
The MES  13 cells were washed three times with 10 mM
phosphate-buffered saline (pH 7.4), mixed with 2.5% sul-
fosalicylic acid (SSA), and subjected to sonication and
centrifugation. The clear supernatants were ﬁnally used for
determining  tGSH and GSSG (oxidized GSH) by the method
of  [28], as described previously [15]. rGSH was computed
by  subtraction (rGSH tGSH GSSG). The pellets were sub-
jected  to protein determination [23] and used to normalize
the  values of tGSH and GSSG. The intracellular REDST of
MES  13 cells was deﬁned as rGSH2 GSSG−1.
2.8. TNF-˛, Thromboxane B2 and nitrite determination
The release of TNF- and Thromboxane B2 (Abnova
GmbH, Heidelberg, Germany) were determined using an
enzyme-linked immunosorbent assay (ELISA) according
to  the manufacturer’s instructions. Total nitrite formed
from NO release into the culture medium was  spec-
trophotometrically determined by using the Griess reagent
(Sigma-Aldrich, St. Louis, USA). The optical densities were
measured at 540 nm with the Sunrise ELISA Reader (Tecan,
Salzburg, Austria).
2.9.  Apoptosis assay
MES  13 cells were seeded in 24-well plates at a
density of 5 × 104 cells per well and the substances
under test were added at various concentrations as indi-
cated.  Apoptotic cells were identiﬁed by YO-PRO-1 (1 M)
staining  [13] in combination with the Hoechst 33342
dye (5 g/ml) (Mobitec Company, Göttingen, Germany)eports 1 (2014) 843–857
as  previously described [7]. The apoptotic cells were
counted and their percentage determined as described
earlier, using an inverse ﬂuorescence microscope Eclipse
TS100  (Nikon GmbH, Du˝sseldorf,  Germany) provided
with a camera AxioCam MRc  (Carl Zeiss Microscopy
GmbH, Göttingen, Germany) and a computer-assisted mor-
phometry  system AxioVision 4 (Carl Zeiss Microscopy
GmbH).
2.10. SDS-PAGE and Western blot
MES 13 cells were scraped off in RIPA buffer pH 7.5 (Cell
Signaling Technology Europa, Leiden, The Netherlands). An
aliquot  was used for protein quantiﬁcation using PierceTM
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
USA), and after addition of sample buffer, pH 8.3, boiled
at  95 ◦C (10 min). Samples were stored at −20 ◦C. After-
wards, electrophoresis was  done using NuPAGE® Novex®
4–12% Bis–Tris Gels, pre-cast polyacrylamide gels (Life
Technologies GmbH, Darmstadt Germany) and a loading of
30  g total protein per lane. Additionally, prestained peq-
GOLD  Protein-Marker VI (PEQLAB Biotechnologie GmbH,
Erlangen Germany) was  used. Blotting was  performed
with wet/tank blotting systems (Bio-Rad Laboratories
GmbH, München Germany) and nitrocellulose Amersham
HybondTM-ECL membrane (GE Healthcare Europe GmbH,
Glattbrugg, Switzerland) for enhanced chemiluminescence
(ECL). Protein transfer was  done at 0.6 mA/cm2 (overnight,
rt) with transfer buffer containing 10% methanol. Non-
speciﬁc sites were blocked with TTBS 5% milk (150 mM
NaCl,  10 mM Tris/HCl, pH 7.6; Tween-20 0.1%; 5% low-
fat  dried milk; 1 h, rt). Rabbit polyclonal antibodies
against active caspase-3 (ab2302, 1:200, Abcam, Cam-
bridge, UK.); Atg5 (A0731, 1:1000, Sigma-Aldrich); BAX
(Ab7977, 1:1000, Abcam); glutathione synthetase (GSS)
(ab91591, 1:200, Abcam); PCNA (13110, 1:1000, New
England Biolabs, UK); p62/SQSTM1 (P0068, 1:500, Sigma-
Aldrich) PTGS2 (Ab15191, 1:200, Abcam) or -tubulin
(ab4074, 1:1000, Abcam) were used diluted in blocking
buffer, overnight, 4 ◦C. An anti-rabbit IgG peroxidase con-
jugate  (1:3000, GE Healthcare Europe GmbH, Germany) in
blocking  buffer; 1 h, rt) and the chemiluminescence ECL
detection kit, AceGlowTM (PEQLAB Biotechnologie GmbH)
were  used for detection. A FUSION-FX7 system (PEQLAB
Biotechnologie GmbH) served for documentation. Wash-
ing  steps after every incubation period were performed
using TTBS. Signals were quantiﬁed by computer soft-
ware  (Scion ImageJ, National Institutes of Health, Bethesda,
USA).
2.11.  Statistical analyses
The  SigmaPlot® 12 software was  used to carryMann–Whitney U-test were used, as well as Pearson’s
product moment correlation test of gene expression. Data
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. Results
.1. Determination of cytotoxic concentrations of
etorolac and Gentamicin
In  vitro experiments were performed using the intra-
lomerular SV40-transformed mouse mesangial cell line
MES  13). These cells show characteristics of intraglomeru-
ar mesangial cells, e.g., expressing cytoskeletal -SM
ctin and -Tubulin, as well as phagocytic properties (not
hown).  Fig. 1A shows the cytotoxic effects of Ketorolac
n MES  13 cells. MES  13 cells depicted as a plot of per-
ent of cytotoxicity, or cell death rate, after 24 h of drug
xposure versus drug concentration. Four different Ketoro-
ac  concentrations spanning a log-range (0.1 mM to 1 mM)
ere  tested, showing progressive escalation in the degree
f  cytotoxicity commensurate with increasing Ketoro-
ac  concentration. At the highest Ketorolac concentration
1 mM)  tested, cytotoxicity was signiﬁcantly (p < 0.05) 5.3-
old  increased compared with the negative control. Fig. 1B
hows  the cytotoxic effects of Gentamicin concentration
ver a log-range beginning at 0.5 mM and going up to 5 mM.
igniﬁcant degrees of cytotoxicity were ﬁrst noted at a Gen-
amicin  concentration of 2.5 mM (p < 0.05), and was  highly
igniﬁcant at 5 mM (p < 0.001). The cell culture model uti-
izing  mouse MES  13 cells correlated nephrotoxic drug
ig. 1. Cytotoxic effects of 24 h treatment with Ketorolac (A) or Gentamicin (B
=control, =0% cytotoxicity)] are given as mean + SEM; * p ≤ 0.05, ** p ≤ 0.001 (by t-t
xperiments.eports 1 (2014) 843–857 847
concentration and cytotoxic potential for both compounds.
When assessed by linear regression analysis, Ketorolac
had the highest correlation coefﬁcient (r-values: 0.991 vs.
0.984)  and consequently, the greatest level of statistical
signiﬁcance (p-values: 0.009 vs. 0.016) compared to gen-
tamicin.  Hence, Ketorolac was  selected as the prototypic
nephrotoxin in our cell culture model for testing with all 3
lipid  emulsions containing n3-PUFAs.
3.2. Inﬂuence of lipid emulsions on cytotoxic effects of
Ketorolac or Gentamicin
The  three highest concentrations of Ketorolac (0.25 mM,
0.5  mM,  1 mM)  – with 9–23% cytotoxicity (Fig. 1A) – were
tested with all three LipOmega-3 emulsions with Fish Oil
(FO)  derived Triglyceride and Medium Chain Triglyceride
(MCT) ratios or FO/MCTs of “9/1, 7/3, 5/5” against the con-
trol  emulsion Lipofundin N at ﬁnal lipid concentrations in
cell  cultures at 0.005% (Fig. 2A–D), 0.010% (Fig. 3A–D) and
0.020% (Fig. 4A–D). Clearly, of the multiple FO/MCT ratios
and  lipid concentrations in cell culture, LipOmega-3 “9/1”
in  cell culture provided superior levels of cytoprotection, as
only  this formulation was  protective against demonstrable
toxicity at all doses of Ketorolac and signiﬁcantly so for all
but  one dose as shown in Fig. 4C. Thus, this FO/MCT com-
bination was  used in all subsequent studies of Gentamicin
) on MES  13 cells. Values [in % cytotoxicity of cells without treatment
est) signiﬁcance vs. cells without treatment (=control); n = 6 independent
848 G.A. Bonaterra et al. / Toxicology Reports 1 (2014) 843–857
Fig. 2. Effects in MES  13 cells of 24 h pre-treatment with 0.005% LipOmega-3 “5/5” (A), LipOmega-3 “7/3” (B), LipOmega-3 “9/1” (C) or Lipofundin N (O-6
tment w
ﬁcance LCT)  (D) on cytotoxic effect of 24 h treatment with Keterolac (after trea
[=control,  =0% cytotoxicity]) are given as mean + SEM; p, (by t-test) signi
n  = 6 independent experiments.toxicity (Fig. 5A–C) and, for all markers of e.g., cell death.
LipOmega-3 “9/1” was signiﬁcantly protective at both toxic
levels  of gentamicin, 2.5 mM Gentamicin and 5 mM Genta-
micin  (Fig. 5A–C).ith the emulsions). Values (in% cytotoxicity of cells without treatment
vs. Ketorolac treatment, using 4–6 wells per treatment and experiment;Although  there was  some suggestion of relief of cyto-
toxicity with the lower concentrations of ﬁsh oil of the
three  FO/MCT ratios, with an isolated case of signiﬁcant
reduction, this was  limited (i.e., LipOmega-3 “5/5”: 0 of 9
G.A. Bonaterra et al. / Toxicology Reports 1 (2014) 843–857 849
F a-3 “5/5
L ment w






lig. 3. Effects in MES  13 cells of 24 h pre-treatment with 0.01% LipOmeg
CT)  (D) on cytotoxic effect of 24 h treatment with Keterolac (after treat
=control,  =0% cytotoxicity]) are given as mean + SEM; * p ≤ 0.05, ** p ≤ 0.01
ell culture conditions as shown in Figs. 2A, 3A and 4A;
ipOmega-3 “7/3”: 1 of 9 cell culture conditions as shown
n  Figs. 2B, 3B and 4B. Similarly, in the Lipofundin, soybean
il  control: 1 of 9 cell culture conditions as shown in 2D, 3D
nd  4D. However, in the emulsion containing the highest
evel  of omega-3 enriched ﬁsh, i.e., LipOmega-3 “9/1”, 8 of” (A), LipOmega-3 “7/3” (B), LipOmega-3 “9/1” (C) or Lipofundin N (O-6
ith the emulsions). Values (in % cytotoxicity of cells without treatment
est) signiﬁcance vs. Ketorolac treatment; n = 6 independent experiments.
9  cell culture conditions as shown in Figs. 2C, 3C and 4C
were  cytoprotective. Consequently, further analyses (i.e.,
inﬂammation-related or apoptosis-related measures of cell
death)  of the effects of n3-PUFAs on key biochemical
processes were conducted on this formulation, in combi-
nation with the highest concentration of the nephrotoxins




t experiFig. 4. Effects in MES  13 cells of 24 h pre-treatment with 0.02% LipOmeg
LCT)  (D) on cytotoxic effect of 24 h treatment with Keterolac (after trea
[=control,  =0% cytotoxicity]) are given as mean + SEM; p, signiﬁcance vs. K
p ≤ 0.01 (by t-test) signiﬁcance vs. Ketorolac treatment; n = 6 independen
studied, to help further understand the mechanism(s)
responsible for the observed cytoprotection against the
nephrotoxins investigated.
When  the lipid emulsions in cell culture were added
at  the same time as the nephrotoxin (co-incubation vs.” (A), LipOmega-3 “7/3” (B), LipOmega-3 “9/1” (C) or Lipofundin N (O-6
ith the emulsions). Values (in % cytotoxicity of cells without treatment
c treatment, using 4–6 wells per treatment and experiment. * p ≤ 0.05, **
ments.
pre-incubation of cells), the cytoprotective effects of the
LipOmega-3 “9/1” were lost (data not shown). As suspected,
the  nephrotoxins tested were as water-soluble salts, which
would  therefore reside in the aqueous phase with imme-
diate  and toxic exposure to the mesangial cells in culture.
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lig. 5. Effects in MES 13 cells of 24 h pre-treatment with 0.005% (A), 0.01
reatment  with the emulsions). Values [in % cytotoxicity of cells without t
entamicin  treatment; n = 6 independent experiments, using 4–6 wells p
reatment;  n = 6 independent experiments.
.3. Effect of LipOmega-3 “9/1” on
etorolac-/Gentamicin-mediated inﬂammation-relevant
arameters
For all studies of proliferation- and inﬂammation-
elevant parameters, only the highest concentration of
ach  nephrotoxin was assessed. Supplementary Table
 provides a summary of several proliferation- and
nﬂammation-relevant parameters taken from both the
entamicin and Ketorolac studies. With respect to Gen-
amicin, there were signiﬁcant (p ≤ 0.01) elevations in
he  release of TNF, NO and TXB2 when cells were
re-incubated with LipOmega-3 “9/1” and Gentamicin
ompared with Gentamicin alone, and this was associ-
ted with a signiﬁcant (p < 0.04 and p < 0.03) heightened
ntracellular Redox state to withstand oxidative stress
n  cells pre-treated with LipOmega-3 “9/1” and Ketoro-
ac  or Gentamicin, respectively (Fig. 6A) compared withr 0.02% (C) on cytotoxic effects of 24 h treatment with Gentamicin (after
t (=control, =0% cytotoxicity)] are given as mean + SEM; p, signiﬁcance vs.
ent and experiment. *** p ≤ 0.001 (by t-test) signiﬁcance vs. Gentamicin
the  nephrotoxins alone. Fig. 6B shows the intracellu-
lar concentration of total glutathione (tGSH) in % of the
untreated control (=100%). Pre-treatment of MES  13 with
0.01%  LipOmega-3 “9/1” resulted in a signiﬁcant (p ≤ 0.001)
about  50% increase in tGSH, whereas 1 mM Ketoro-
lac signiﬁcantly (p ≤ 0.05) reduces the tGSH about 50%
(Fig.  6B); however, pre-treatment with LipOmega-3 “9/1”,
signiﬁcantly (p ≤ 0.01) improved/restored the Ketorolac-
mediated decreased tGSH levels almost to control levels
(Fig.  6B). Additionally, pre-treatment of MES  13 with 0.01%
LipOmega-3 “9/1” also resulted in an about 50% increase
in  rGSH, whereas 1 mM Ketorolac signiﬁcantly (p ≤ 0.05)
reduces the rGSH about 50% (Fig. 6C); however, pre-
treatment with LipOmega-3 “9/1”, signiﬁcantly (p ≤ 0.01)
improved/restored the Ketorolac-mediated decreased
rGSH levels almost to control levels (Fig. 6C).
As already shown for Ketorolac, also Gentamicin
decreases the tGSH content by about 20% (Fig. 6D) and
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Fig. 6. Effects in MES  13 cells of 24 h pre-treatment with 0.01% LipOmega-3 “9/1” on Gentamicin/Ketorolac induced cytotoxicity: Changes in glutathione
metabolism.  (A) mRNA expression of glutathione synthetase (GSS), glutathione reductase (GSR) [measured by qRT-PCR] and biochemically quantiﬁed
intracellular  glutathione (GSH) Redox state (=rGSH2/GSSG); p, signiﬁcance (by t-test) nephrotoxin (Ketorolac or Gentamicin) plus 0.01% LipOmega “9/1”
pre-treatment  vs. nephrotoxin alone; values are given as mean of 3–4 independent experiments. NS, not signiﬁcant. (B) and (D), intracellular total GSH
(tGSH);  (C) and (E), intracellular reduced GSH (rGSH). (F) and (G) Western blot of GSS protein expression, quantiﬁed by densitometric analysis using ImageJ
software;  (H) representative Western blot of GSS expression. (B)–(G). Values expressed in % of control (100%) are given as mean + SEM. # p ≤ 0.05, (by t-test)


























































MG.A. Bonaterra et al. / Toxi
igniﬁcantly (p < 0.05) about 50% the rGSH content in
omparison with the control (Fig. 6E). Once again, pre-
reatment with LipOmega-3 “9/1”, signiﬁcantly (p ≤ 0.01;
 ≤ 0.001) improved/restored the Gentamicin-mediated
educed tGSH and rGSH levels to higher than control
evels (Fig. 6D and E). GSS is an enzyme essential for
lutathione synthesis. Thus we tested GSS expression by
RT-PCR  and Western blotting. We  found that, Ketoro-
ac  and Gentamicin alone signiﬁcantly (p ≤ 0.05) affect
rotein expression of GSS (Fig. 6F and G). However, pre-
reatment with LipOmega-3 “9/1” improved/restored the
ephrotoxin-mediated GSS effects up to (in case of Gen-
amicin) or about 70% higher (in case of Ketorolac) than
ontrol levels (Fig. 6F and G).
Furthermore, in the Ketorolac studies, pre-incubation
ith LipOmega-3 “9/1” resulted in signiﬁcant (p ≤ 0.001
nd  p ≤ 0.05) reductions of nephrotoxin-mediated increase
n  PCNA-mRNA expression and TXA Synthetase levels,
espectively (Supplementary Table 1). In both cases, the
verall  cytoprotective effects of LipOmega-3 were signif-
cant.  Western blot analyses of PCNA protein expression
ould partly conﬁrm the qRT-PCR data (Supplementary
ig. 1A–C). Moreover, Ketorolac treatment (1 mM)  leads to
n  induction of PTGS2 (prostaglandin-endoperoxide syn-
hase  2/prostaglandin G/H synthase/cyclooxygenase) on
NA  and protein level (Supplementary Table 1 and Sup-
lementary Fig. 1D and F), which could not be decreased
o control levels by pre-incubation with LipOmega-3 “9/1”
Supplementary Table 1 and Supplementary Fig. 1D and F).
reatment  of MES  cells with Gentamicin w/o LipOmega-
 “9/1” did not alter PTGS2 expression (mRNA & protein)
Supplementary Table 1 and Supplementary Fig. 1E and F).
.4.  Effect of LipOmega-3 9/1 on Ketorolac/Gentamicin
ediated apoptosis-relevant parameters
Fig. 7A provides a summary of the apoptosis-relevant
arameters taken for both, the Ketorolac and Gentamicin
tudies. Ketorolac is associated with signiﬁcant increases
n  apoptosis-related gene expression for each of the two
egulator proteins BCL2, and the enzyme caspase-3 that
as  signiﬁcantly (p ≤ 0.05) about 50% diminished when the
ells  were pre-treated with LipOmega-3 despite no signif-
cantly  relevant change of apoptosis between Gentamicin
lone and with LipOmega-3 “9/1” (Fig. 7A). For all studies
f  apoptosis-relevant parameters, only the highest con-
entration of each nephrotoxin was assessed. Incubation
f  MES13 cells with 1 mM Ketorolac (Fig. 7B) or Genta-
icin (5 mM;  Fig. 7C) alone leads to a signiﬁcant about
-fold induction of apoptosis compared with untreated
ontrol. Although not signiﬁcant, Fig. 7B and C shows a net
bout  6-fold or 4-fold increase in apoptosis (% apoptosis)
rom the nephrotoxins when the cells are pre-incubated
ith LipOmega-3 “9/1” and afterwards with nephrotoxins.
ctivated caspase-3 plays a central role during apopto-
is  execution. Thus, we performed Western blotting to
easure protein expression of active caspase-3. We  found
re-treatment of MES  13 cells with LipOmega-3 “9/1”
esulted in an about 20% inhibition of protein expression of
ctive  caspase-3 in comparison with the control (Fig. 7D–F).
oreover, Ketorolac—in contrast to Gentamicin, increasedeports 1 (2014) 843–857 853
the  protein expression of active caspase-3 about 50%
(Fig.  7D–F). Furthermore, pre-treatment of MES  13 cells
with  LipOmega-3 “9/1” and afterwards with 1 mM Ketoro-
lac  resulted in an about 140% increase in protein expression
of  active caspase-3 in comparison with the untreated
control and an about 90% increase in comparison with
Ketorolac treated MES  13 cells (Fig. 7D and F). No signif-
icant differences were observed when the MES  13 were
treated with Gentamicin alone or after pretreatment with
LipOmega-3 “9/1” and afterwards with Gentamicin (Fig. 7E
and  F).
Despite a signiﬁcant decrease (p ≤ 0.05) of the BAX
mRNA expression (Fig. 7A) after pre-treatment with
LipOmega-3 “9/1” and Ketorolac, no signiﬁcant difference
in  the protein expression of the pro-apoptotic BAX was
observed neither after pre-treatment with LipOmega-3
“9/1”, Ketorolac or Gentamicin alone nor with nephrotox-
ins  together with LipOmega-3 (Supplementary Fig. 1G–I).
Additional investigations of the expression (protein level)
of  the ubiquitin-binding autophagic adaptor p62/SQSMT1
(hereafter p62) showed a signiﬁcant (p < 0.001) inhibition
by  70% after pre-treatment with LipOmega-3 “9/1” and
afterwards with Ketorolac when compared with the con-
trol  or Ketorolac (p < 0.05) (Supplementary Fig. 2A and C).
Pre-treatment with LipOmega-3 “9/1” and afterwards Gen-
tamicin  exhibited a signiﬁcant (p < 0.001) 100% increase in
the  protein-expression of p62 when compared with the
control  or Gentamicin (p < 0.05) (Supplementary Fig. 2B
and  C). Because there are 38 known autophagy-related
(Atg) genes regulating the steps of autophagosome forma-
tion  and breakdown [16] we have just investigated in our
system  the ubiquitin-like conjugation system Atg5-Atg12-
Atg16, that is responsible for vesicle expansion (Lippai and
Löw,  2014). Atg5 (also known as Apg5) forms a covalent
complex with Atg12. We  found that after pre-treatment
with LipOmega-3 “9/1” and afterwards Ketorolac the
Atg5-Atg12 protein-expression was  signiﬁcantly (p < 0.05)
inhibited  when compared with Ketorolac (Supplementary
Fig. 2D and F). However, no signiﬁcant difference in the pro-
tein  expression of Atg5-Atg12 was  observed neither after
pre-treatment with LipOmega-3 “9/1” and afterwards Gen-
tamicin  nor with Gentamicin alone (Supplementary Fig. 2E
and  F).
4.  Discussion
It is important to distinguish the biochemical effects
elicited by the different nephrotoxins, as well as those
resulting from the different fatty acid proﬁles among
the lipid-based culture media studied. Ketorolac is a
non-steroidal anti-inﬂammatory drug (NSAID) frequently
prescribed in its intravenous form for postoperative pain
management that provides opiate-like analgesia without
the  accompanying adverse reactions. All NSAIDs share
a  common mechanism of pharmacological action that
includes blockade or inhibition of the critical cyclooxygen-
ase isoenzymes, COX-1 and COX-2 that affect eicosanoid
metabolism. COX enzymes play a crucial role in the gener-
ation  of prostaglandins, prostacyclins and thromboxanes
formed from the FA precursors (e.g., arachidonic acid and
eicosapentaenoic acid, which have direct effects on the
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Fig. 7. Effects in MES 13 cells of 24 h pre-treatment of with 0.01% LipOmega-3 “9/1” on Gentamicin/Ketorolac induced cytotoxicity: Changes in apoptosis;
(A)  mRNA expression of apoptosis-relevant parameters BCL-2, BAX and active Caspase-3; p, signiﬁcance (by t-test) nephrotoxin (Ketorolac or Gentamicin)
plus  0.01% LipOmega “9/1” pre-treatment vs. nephrotoxin alone. Values are given as mean of 3–4 independent experiments. NS, not signiﬁcant. (B) and
(C),  morphologically measured apoptosis rate. Values expressed (in % of apoptosis) are given as mean + SEM. # p ≤ 0.05, ### p ≤ 0.001 (by t-test) signiﬁcance
vs.  control; n = 3 independent experiments. (D) and (E) Western blot of active caspase-3 protein expression, quantiﬁed by densitometric analysis using
ImageJ  software; values expressed in % of control (100%) are given as mean + SEM. # p ≤ 0.05, (by t-test) signiﬁcance vs. control (=100%). * p ≤ 0.05, (by t-test)
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ody’s metabolic response to inﬂammation, both locally
nd  systemically [5]. In the kidney, Ketorolac can alter
he  balance of these vasoactive eicosanoids and may  dis-
upt  normal renal hemodynamics with devastating clinical
onsequences. With respect to renal toxicity, there is no
igniﬁcant difference between non-selective COX-1 + COX-
 inhibitors (e.g., ibuprofen, acetominophen) and selective
OX-1  (e.g., ketorolac, indomethacin) or COX-2 (e.g., etori-
oxib,  lumitacoxib) inhibitors [10]. Consequently, despite
he  important potential role of non-opiate parenteral anal-
esics  in medicine, the use of Ketorolac in the critical care
etting  is severely restricted.
Gentamicin belongs to an important class of parenteral
ntimicrobials known as the aminoglycosides. In contrast
o  Ketorolac, Gentamicin is widely used around the world
n  the clinical setting. Nephrotoxicity from this drug has
een  mainly attributed to proximal tubule damage and
bstruction, and a reduction in the glomerular ﬁltration
ate, or GFR. We  focused on the latter mechanism of injury
iven  the effects of Gentamicin to: (1) cause mesangial cell
ontraction, (2) decrease renal blood ﬂow, (3) induce elec-
rostatic  binding between its cationic amino acid groups
ith  negatively charged phospholipids in cell membranes;
nd, (4) promote vasoconstrictive prostanoids (e.g., throm-
oxane  A2) [17].
According  to the literature tubular effects cannot solely
xplain the reduced glomerular ﬁltration rate [20,17], the
njury  must also include biochemical consequences that
ccentuates renal damage (i.e., exaggerated thromboxane
-2 production causing pronounced vasoconstriction and
schemia.  Which mechanism (mechanical and/or biochem-
cal)  is most responsible is difﬁcult to explain. When we
epeated these studies in the proximal tubule cell cul-
ures, we did not observe cytoprotection, but only in MES
ells,  which might suggest an important role of these cells
n  mitigating damage. We  used a cell culture model, and
ence,  this investigation is a ﬁrst approximation to help
stablish proof-of-concept but we cannot assert the clin-
cal  relevance of the data. Our next investigations will
e  in an intact animal model to prove or disprove the
ytoprotective role of the MES  cells when exposed to a
etabolically active substrate substrate(s), i.e., EPA and
HA,  that reduces inﬂammation and vasoconstriction from
roximal  tubule damage. An intact animal model would
e  most appropriate to observe the effects in both proxi-
al  tubular cells and MES  cells and to argue for a possible
linical applicability. In each phase of these investigations,
he central issue is cytoprotection from known nephrox-
cants. Thus, dose equivalency to humans is a secondary
ssue to be dealt with if the current in vitro and subse-
uent in vivo pre-human investigations continue to show
rotection against renal injury via omega-3 fatty acids.
or  example, from current clinical experience, we  know
he  incidence of nephrotoxicity from standard intravenous
oses of aminoglycosides, and thus these studies will be
esigned  accordingly to include omega-3 fatty acids with
ach  dose of gentamicin to reduce this adverse effect from
onventional therapy.
Glomerular  apoptosis and proliferation have been
hown in several glomerulosclerotic lesions that either
roliferation or apoptosis (or both) might be (in someeports 1 (2014) 843–857 855
pathophysiological conditions) the consequence of tissue
homeostasis as a response to an insult [20]. It might be
speculated that growing doses of nephrotoxins as gen-
tamicin or Ketorolac would induce further cytotoxicity
(i.e., apoptosis). Apoptotic cells are metabolic active and
we  performed viability test with the reagent Presto Blue
that  detects active cells. Therefore, despite an increased
viability, a pre-incubation with LO-3 might also prolon-
gate the survival of apoptotic cells and thus, an increased
apoptosis rate (detected by microscopical methods [YO-
PRO-1]  or Western blot [active caspase-3]) is found. An
alternative outcome of apoptosis is secondary necrosis
termed also late apoptosis, an autolytic process of cell
disintegration. The early apoptotic cells preserve their
plasma membrane integrity to retain the potentially harm-
ful  cellular contents inside. If not successfully taken up
by  phagocytes, apoptotic cells proceed to the phase of
late  apoptosis when the plasma membrane becomes
permeable for macromolecules [25]. The leakage of intra-
cellular  molecules during secondary necrosis provokes an
inﬂammatory response [8], but the pre-treatment with
LO-3  probably delay secondary necrosis triggered by the
treatment with the nephrotoxic drugs and consequently
inhibit the pro-inﬂammatory response. Associated with
cell  death/apoptosis, autophagy is a constitutive cellu-
lar  event and is enhanced under certain conditions such
drug  treatments [14]. We  found an inhibition of the two
autophagy markers, Atg5 and p62 after pretreatment with
LipOmega-3 “9/1” and subsequent treatment with Ketoro-
lac  Adaptive mechanisms as autophagy are initiated when
the  intensity or duration of stress reaches the limit of the
cell  and suicidal cell death programs are activated [19].
Apoptosis usually is accompanied by a high degree of cas-
pase  activation, as also observed in our results and may
lead  to the cleavage of multiple proteins which promotes
an  apoptotic morphology [19]. In this context caspases
can digest several essential autophagy proteins, result-
ing  in the inactivation of the autophagic program perhaps
with  the goal to abort its cytoprotective function and to
accelerate cellular demise [19] induced e. g. by nephrotox-
ins treatment. On the other hand the pre-treatment with
LipOmega-3 “9/1” may delay the ﬁnal destination of the
cells  with the consequence that these cells remain in an
“apoptotic status” and retard the pro-inﬂammatory path-
way  activation.
In  the kidney, there are two distinct mechanisms of cell
death,  namely by oncosis (necrotic cell death) or by apo-
ptosis,  and each process has a unique cellular presentation
depending upon the concentration of the nephrotoxicant,
with apoptosis generally occurring with low-concentration
toxicities, and oncosis being the general mechanism of
cell  death at high-concentration toxicities [24]. Oncosis
often involves adjoining cells, and causes an increase in
cell  volume and eventual rupture, causing an inﬂamma-
tory response; whereas apoptosis has an opposite reaction
involving individual cells and a decrease in cell volume
without inﬂammation.The  lipid-based emulsions used in cell culture also
included an omega-6 acid-enriched triglyceride (20% soy-
bean  only oil-in-water emulsion). This emulsion contains
large  quantities of the omega-6 fatty acid linoleic acid,
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a precursor to arachidonic acid, or AA [2], comprising
approximately 50% of the fatty acid proﬁle of soybean oil
triglycerides. Omega-6 fatty acids are pro-inﬂammatory by
virtue  of the metabolic conversion (via the COX pathway)
of  AA-derived lipid mediators, including the vasoactive
eicosanoids of the 2-series, prostaglandin E2, prostacy-
clin I2 and thromboxane A2. In contrast, the omega-3 acid
enriched triglycerides from the 3 test emulsions contain
increasing concentrations of EPA + DHA, wherein EPA is the
preferential substrate over AA for the COX enzymes [2]. This
results  in the formation of EPA-derived lipid mediators, but
of  the less vasoactive, and less pro-inﬂammatory 3-series of
the  above eicosanoids. Hence, depending on the fatty acid
substrate, the inﬂammatory response can be exaggerated
or up-regulated (i.e., AA substrate), or alternatively, it may
be  down-regulated or modulated (i.e., EPA-substrate).
Thus, multiple mechanisms of injury and repair (e.g.,
structural alteration of the integrity of cell membranes,
inhibition of key metabolic enzymes, modiﬁed response
based on lipid substrate) of cells are facilitated by variable
alterations in phospholipid metabolism caused by both the
nephrotoxins and the lipid-based emulsions studied in cell
culture.  Recognizing the importance of phospholipid medi-
ators  involved: (1) in terms of membrane stability; (2)
the  metabolic response to injury (inﬂammation, oxidative
stress, and ischemia), as well as, (3) the predilection for
omega-3 fatty acids as the preferred metabolic substrate
over omega-6 fatty acids eicosanoid metabolism [2], assists
in  interpreting the results from these studies. For exam-
ple,  the provision of pro-inﬂammatory omega-6 fatty acids,
along  with the nephrotoxin studied, would be expected to
either  accentuate the cytotoxic response, or have no ben-
eﬁcial  effect on cytoprotection. With the exception of one
isolated  case at the highest concentration of the nephro-
toxin (Fig. 4D), this is precisely what was observed in this
study.
In  contrast, the provision of less pro-inﬂammatory
omega-3 fatty acids in the presence of nephrotoxins should
be  cytoprotective. With regards to inﬂammation-related
cell death, there were signiﬁcant reductions in the over-
all  %-cytotoxicity for both nephrotoxins studied when the
mesangial  cell cultures were pre-incubated with omega-
3  fatty acids. The optimum response was achieved with
the  LipOmega-3 with a FO/MCT ratio of 9/1, and in a
cell  culture concentration of 0.010%. The cytoprotective
effects occurred at all Ketorolac concentrations studied,
whereas such effects were present only at the two high-
est  concentrations of Gentamicin. This difference most
likely  reﬂects the dissimilar mechanisms of cell injury
between nephrotoxins. For example, Ketorolac blocks the
COX  enzymes involved in the de novo generation of
prostaglandins, among the most responsible for main-
taining renal hemodynamics. Evidence of this effect was
observed by signiﬁcant reductions in gene expression of
thromboxane synthase, which was accompanied by signif-
icant  reductions in expression of the PCNA gene involved
in  the DNA repair pathway. This was also associated with
a  signiﬁcantly elevated intracellular redox state generally
consistent with an improved energy state and a heightened
ability to manage oxidative stress. In this context, the pro-
tective  effect of LipOmega-3 “9/1” is clearly shown at theeports 1 (2014) 843–857
level  of GSS protein expression. The pre-treatment with
LipOmega-3 “9/1” enhances the expression of GSS, enzyme
responsible for the glutathione (tGSH) synthesis with well
know  anti-oxidative function. The protective effect may  be
corroborated by the increase of intracellular rGSH observed
in  the MES  13 cells after pre-treatment with LipOmega-
3 “9/1” alone or afterwards with nephrotoxins, meaning
that most of the produced tGSH probably is converted
in rGSH as a result of LipOmega-3 “9/1” effect and con-
sequently improves the intracellular redox state and the
anti-oxidative defense against the nephrotoxins Ketorolac
and  Gentamicin.
On  the other hand, Gentamicin, which, in part, dis-
rupts prostaglandin synthesis by altering the integrity of
cell  membranes, caused signiﬁcant increases in TNFal-
pha, nitric oxide production and thromboxane B2 release
from  mesangial cells suggesting a greater inﬂammatory
response to its nephrotxic effects, as well as alterations in
renal  hemodynamics that favor ischemia. The increase in
redox  state in this instance presumably reﬂected a compo-
nent  of the compensatory response to inﬂammatory stress.
Although apoptosis increased for both nephrotoxins, the
effects  were not signiﬁcant except when the nephrotoxin
plus lipid LipOmega-3 “9/1” were compared vs the nephro-
toxin  alone. However, Ketorolac and to a more limited
extent Gentamicin were both associated with signiﬁcant
increases in the expression of several apoptosis-related
genes and active caspase-3 protein expression. This would
suggest  limited to no tendency for reduction in apopto-
sis  by the lipid. Therefore inﬂammation-related death does
indeed  appear to be the more dominant mechanism for cell
death,  compared to apoptosis, with the data suggesting that
modulation  of eicosanoid production (prostaglandin and
thromboxane, respectively) via omega-3 fatty acids signiﬁ-
cantly  reduces the cytotoxicity of the nephrotoxins studied,
although by distinctly different mechanisms.
5. Conclusions
The ﬁndings of greater toxicity, particularly at the higher
concentrations of nephrotoxins in this study, as well as
the  cellular presentations from necrosis and apoptosis
observed in the mouse mesangial cells used, are consistent
with current expert toxicological views on the important
biochemical mechanisms and mediators of renal cell injury
[24].  Preincubation of MES  13 cells with omega-3 fatty
acids  mitigates cell damage from two injectable nephro-
toxins with different mechanisms of injury. In the present
context, the inclusion of omega-3 fatty acids may  play an
important therapeutic role to offset the nephrotoxicity of
selected  drugs used in the clinical setting. This would be
a  distinctly different therapeutic role for particular lipid
components compared to the conventional application of
drug  vehicles as delivery systems for poorly water-soluble
drugs. As a ﬁrst approximation, we  have established proof-
of-concept in a cell culture model using intraglomerular
mesangial cells. The next phase of research will need to be
performed in an intact animal model (e.g., rodent) and with
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mulsion to conﬁrm these ﬁndings that support the con-
ept  of a therapeutic drug vehicle.
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